Research and Development Investment: Pfizer Inc. vs Apellis Pharmaceuticals, Inc.

Pfizer vs Apellis: A Decade of R&D Investment

__timestampApellis Pharmaceuticals, Inc.Pfizer Inc.
Wednesday, January 1, 201483795228393000000
Thursday, January 1, 2015137303117690000000
Friday, January 1, 2016229785997872000000
Sunday, January 1, 2017403038787657000000
Monday, January 1, 20181052855768006000000
Tuesday, January 1, 20192209687708650000000
Wednesday, January 1, 20202999210009405000000
Friday, January 1, 202142086900013829000000
Saturday, January 1, 202238723600011428000000
Sunday, January 1, 202335438700010679000000
Monday, January 1, 202410930000000
Loading chart...

Igniting the spark of knowledge

A Decade of Innovation: Pfizer Inc. vs Apellis Pharmaceuticals, Inc.

In the ever-evolving landscape of pharmaceutical research, the investment in Research and Development (R&D) is a critical indicator of a company's commitment to innovation. Over the past decade, Pfizer Inc. and Apellis Pharmaceuticals, Inc. have demonstrated contrasting strategies in their R&D expenditures.

From 2014 to 2023, Pfizer consistently allocated substantial resources to R&D, with an average annual investment of approximately $9.4 billion. This represents a steadfast commitment to innovation, with a peak in 2021, where R&D expenses soared by nearly 50% compared to 2014. In contrast, Apellis Pharmaceuticals, a smaller player, showed a remarkable growth trajectory, increasing its R&D spending by over 4000% during the same period.

This data underscores the diverse approaches within the pharmaceutical industry, where both giants and emerging companies play pivotal roles in advancing medical science.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025